Substance / Medication

Galantamine hydrobromide

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Pharmacokinetics and bioequivalence studies of galantamine hydrobromide dispersible tablet in healthy male Chinese volunteers.
Zhang Li-jun, Fang Xiao-ling, Li Xue-ning et al. · Drug Dev Ind Pharm · 2007
PMID: 17454066RCT
Canagliflozin prevents scopolamine-induced memory impairment in rats: Comparison with galantamine hydrobromide action.
Arafa Nadia M S, Ali Elham H A, Hassan Mohamed Kamel · Chem Biol Interact · 2017
PMID: 28837785Observational
Stability-indicating study of the anti-Alzheimer's drug galantamine hydrobromide.
Marques Lygia Azevedo, Maada Ismail, de Kanter Frans J J et al. · J Pharm Biomed Anal · 2011
PMID: 21300511Observational
A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease.
Grace J, Amick M M, Friedman J H · J Neurol Neurosurg Psychiatry · 2009
PMID: 18931006Observational
Bullous pemphigoid precipitated by galantamine hydrobromide.
Diab Mohammad, Coloe Jacquelyn, Bechtel Mark A · Cutis · 2009
PMID: 19363906Case Report
Studies on pomegranate seed oil enriched galantamine hydrobromide microemulsion: formulation, in vitro antioxidant and neuroprotective potential.
Shrivas Meenakshee, Khunt Dignesh, Shrivas Meera et al. · Pharm Dev Technol · 2023
PMID: 36662596Other
PVC membrane, coated-wire, and carbon-paste ion-selective electrodes for potentiometric determination of galantamine hydrobromide in physiological fluids.
Abdel-Haleem Fatehy M, Saad Mohamed, Barhoum Ahmed et al. · Mater Sci Eng C Mater Biol Appl · 2018
PMID: 29752082Other
[Serious cutaneous reactions to galantamine hydrobromide (Reminyl® and generics)].
Schmutz J-L · Ann Dermatol Venereol · 2016
PMID: 26899423Other
[The Regulation of AMPKα1/Nrf2/ HO-1 Pathway Mediated by Galantamine Hydrobromide Lycoremine in Myocardial Ischemia Reperfusion Rats].
Zeng Fei, Li Qiang, Zeng Bian et al. · Sichuan Da Xue Xue Bao Yi Xue Ban · 2020
PMID: 32543139Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Galantamine hydrobromide (substance)
SNOMED CT
129482002
UMLS CUI
C0949312

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.